Skip to main content

Table 1 Baseline clinical characteristics of the study population

From: Clinical outcomes and hemodynamic performance of Dafodil™ aortic and mitral pericardial bioprosthesis: 1-year results from Dafodil-1 first-in-human trial

Demographic characteristicsTotal
n = 60 patients
AVR
n = 30 Patients
MVR
n = 30 Patients
Age (years), (mean ± SD)53.95 ± 12.0959.83 ± 8.3348.57 ± 12.63
Age groups, n (%)
 ≤ 60 years40 (66.67)17 (56.67)23 (76.67)
 61–70 years19 (31.67)12 (40.0)7 (23.33)
 > 70 years1 (1.67)1 (3.33)0 (0.00)
Gender, n (%)
 Male33 (55)21 (70)12 (40)
 Female27 (45)9 (30)18 (60)
Body mass index (kg/m2), (mean ± SD)23.15 ± 4.8324.16 ± 4.4121.58 ± 4.35
STS risk of mortality, % (mean ± SD)1.18 ± 0.631.38 ± 0.82
Cardiopulmonary bypass time (minutes), (mean ± SD)129.56 ± 45.72148.77 ± 62.81114.69 ± 27.01
Co-morbidities, n (%)
 Smokers4 (6.67)3 (10)1 (3.33)
 Diabetes mellitus5 (8.33)4 (13.33)1 (3.33)
 Hypertension13 (21.67)9 (30)4 (13.33)
Previous Cardiac events/surgeries
 Previous MI1 (1.67)1 (3.33)0 (0.00)
 Previous PCI1 (1.67)1 (3.33)0 (0.00)
 Cerebrovascular events2 (3.33)0 (0.00)2 (6.67)
 Previous valvuloplasty1 (1.67)0 (0.00)1 (3.33)
 Congestive heart failure1 (1.67)1 (3.33)0 (0.00)
Etiology, n (%)
 Rheumatic33 (55.00)11 (36.67)22 (73.33)
 Degenerative27 (45.00)19 (63.33)08 (26.67)
Concomitant procedures, n (%)20 (100)10 (50.00)10 (50.00)
 Coronary artery bypass grafts7 (35.00)4 (40.00)3 (30.00)
 Mitral valve repair3 (15)3 (30.00)0 (0.00)
 Tricuspid valve repair7 (35.00)0 (0.00)7 (70.00)
 Aortic root enlargement2 (10.00)2 (20.00)0 (0.00)
 Ascending aorta replacement1 (5.00)1 (10.00)0 (0.00)
  1. AVR Aortic valve replacement, MI Myocardial infarction, MVR Mitral valve replacement, PCI Percutaneous coronary intervention, STS The Society of Thoracic Surgeons